Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.18.6239DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
4
myeloma presenting
4
presenting colonic
4
colonic obstruction
4
obstruction bony
4
bony lesions
4
lesions clinical
4
clinical dilemma
4
multiple
1
presenting
1

Similar Publications

Heightened clinical vigilance for multiple myeloma is essential in patients presenting with atypical chronic pain progression. Symptoms may overlap with degenerative musculoskeletal conditions, frequently leading to misdiagnosis. This underscores the necessity of a thorough evaluation when symptoms are refractory to conventional therapies, in order to facilitate timely diagnosis and effective management of malignancy.

View Article and Find Full Text PDF

Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM), but direct comparisons are lacking. Leveraging an international multicenter RRMM cohort, we compared the outcome of ide-cel ( = 162) versus cilta-cel ( = 42). Co-primary efficacy endpoints of the study were overall response rate (ORR) and progression-free survival (PFS).

View Article and Find Full Text PDF

Enhancing staging in multiple myeloma using an m6A regulatory gene-pairing model.

Clin Exp Med

January 2025

Department of Hematology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, People's Republic of China.

Multiple myeloma (MM) is characterized by clonal plasma cell proliferation in the bone marrow, challenging prognosis prediction. We developed a gene-pairing prognostic risk model using m6A regulatory genes and a nested LASSO method. A cutoff of - 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!